Liraglutide: Research, Dosing, and Where to Buy in 2026
A research-first profile for Liraglutide, aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Liraglutide is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 15 PubMed-cited papers, 7 attributed expert mentions, and 2 transcript dosing protocols for Liraglutide, each linked to its source.
- 2 aggregated dosing-protocol mentions from source transcripts.
- 15 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
- Evidence level in this entry is marked as fda_approved.
What is Liraglutide?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 2 cited mentions
"So you know back in the day we only had lerglutide, durlutide and semiglutide to choose from. And llutide was a daily injection which allowed you to basically take it from Monday to Saturday. Sunday you would take a day off if that was your refeed day"
"I found some scientific evidence in liraglutide that GLP-1 receptor agonism, proven with liraglutide, helps with tendon and connective tissue strength."
What is Liraglutide researched for?
Early-generation single GLP-1 receptor agonist; daily dosing allowed off-day refeeds.
Liraglutide Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Vigorous Steve | FULL Quad Tear Recovery Protocol, HGH Serum Tests, Maximize Cardio... | 00:15:18 | Steve reported using daily injections Monday-Saturday, with Sunday off as a refeed day, and described an acute appetite-control dose of 0.6-1.2 mg as needed. | anecdotal |
| Vigorous Steve | Can Retatrutide Kill Your Motivation? Vigorous Steve Explains Dopamine | 00:07:16 | 5-6 days a week with Saturday/Sunday off for refeed | anecdotal |
Where to Buy Liraglutide in 2026
No tracked vendor recommendations for Liraglutide yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
1 expert across our source library discuss Liraglutide. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“So you know back in the day we only had lerglutide, durlutide and semiglutide to choose from. And llutide was a daily injection which allowed you to basically take it from Monday to Saturday....”
See 3 more expert mentions →
-
“I found some scientific evidence in liraglutide that GLP-1 receptor agonism, proven with liraglutide, helps with tendon and connective tissue strength.”
-
“a couple years ago I talked about liraglutide, this is the most favorable one because you could take it 5 6 days a week, and then still have your refeed on Sunday.”
-
“it's not being sold on the peptide websites because they got... cease and desist letters. So, there's no more liraglutide and dulaglutide.”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Liraglutide. Each line links to the original source.
- "The MCAO models were the main models used in stroke studies, with a significant decrease in infarct volume, such as 15.4 % ± 1.3 % (liraglutide) and 40 % reduction with linagliptin." · Parekh D et al, 2026 PubMed
- "The score in neurological deficit was also found to improve (1.1 ± 0.14; P < 0.05) and the size of the infarct in treated groups had also reduced (36.5 % to 8.2 %; P = 0.001)." · Parekh D et al, 2026 PubMed
- "Percentage body-weight change was analyzed separately across 11 independent comparisons and also favored GLP-1RA/incretin-based therapy (MD -9.53 percentage points, 95% CI -11.92 to -7.14; 95% PI -17.58 to -1.48; I2 = 95.4%)." · Bruna-Mejias A et al, 2026 PubMed
- "Reported BMI reductions varied across studies and pharmacological agents, with semaglutide trials reporting reductions of up to -16.1%." · Myśliwczyk D et al, 2026 PubMed
- "Non-diabetic participants achieved the greatest reductions, losing 15.7% of baseline weight at 12 months versus 5.1% in diabetic users in the mixed cohort." · Jia I et al, 2026 PubMed
- "Disproportionality analysis was performed using reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence intervals, applying Evans' criteria, restricted to primary suspect drug reports." · Kakkar A et al, 2026 PubMed
- "Semaglutide demonstrated a strong post-marketing safety signal for optic ischaemic neuropathy (355 reports; ROR 94.45, 95% CI: 83.02-107.45; PRR 93.77, 95% CI: 82.48-106.61)." · Kakkar A et al, 2026 PubMed
- "Tirzepatide and liraglutide also exhibited significant safety signals (49 reports; ROR 2.94, 95% CI: 2.20-3.93; PRR 2.94, 95% CI: 2.20-3.93; and 13 reports; ROR 4.58, 95% CI: 2.65-7.91; PRR 4.58, 95% CI: 2.65-7.91, respectively)." · Kakkar A et al, 2026 PubMed
- "Among semaglutide-associated reports, mean age was 59 years; disability was documented in 18% and hospitalization in 11% of cases." · Kakkar A et al, 2026 PubMed
- "GLP-1RAs use was significantly associated with a lower 5-year risk of cataract (RR: 0.45; 95% CI, 0.40-0.50), AMD (RR: 0.33; 95% CI, 0.23-0.48), ocular hypertension (RR: 0.56; 95% CI, 0.34-0.91), POAG (RR: 0.50; 95% CI, 0.32-0.78) and DES (RR: 0.36; 95% CI, 0.31-0.42)." · Chen K et al, 2026 PubMed
Research and Studies
15 PubMed-indexed papers reference Liraglutide. Top 15 shown.
Legal Status
Liraglutide is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Liraglutide FDA-approved?
Liraglutide is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Liraglutide?
This page aggregates 2 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Liraglutide?
15 PubMed-indexed paper(s) reference Liraglutide in our current research feed. See the Research and Studies section above for citations.